Latest research on Quetiapine

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

Quetiapine indications

A study that examined the effect of antipsychotics on DNA methylation found that Clozapine and Quetiapine reduced the DNA methylation, but there are no similar effects of Haloperidol and Risperidone on DNA methylation status [54]. [source, 2016]
A 12-month, double-blind, non-inferiority study of lurasidone compared with Quetiapine XR provided evidence for the long-term effectiveness of treatment with lurasidone in patients with schizophrenia (Loebel et al., 2013b), which was further supported by data from two six-month, open-label extension studies (Citrome et al., 2014; Stahl et al., 2013) and a 12-month, randomized, double-blind safety study with an active comparator arm (Citrome et al., 2012). [source, 2016]
Similar to the majority of pharmacological agents utilized to treat anxiety disorder which are associated with serotonergic and/or noradrenergic neurotransmission, the possible explanation of the effect of Quetiapine and its metabolite for GAD may be associated with the action on dopaminergic, serotoninergic, and noradrenergic systems or their combined effects. [source, 2016]
Additionally, Quetiapine has a potent antagonist effect on 5-HT2A receptor which explains its sedative effect. [source, 2016]
Since such studies have limited sample sizes, meta-analysis, a more powerful method in determining the true effect size, is a possible strategy to verify the efficacy and acceptability of Quetiapine in the treatment of GAD. [source, 2016]
Based on findings in the present meta-analysis, Quetiapine may have an effective role in the treatment of such patients because of its better Sleep promoting quality compared to SSRIs. [source, 2016]
Although Quetiapine can promote Sleep quality, its sedative effect may negatively impact Daytime functioning. [source, 2016]
Although low dose Quetiapine appears to be effective and tolerable in the treatment of GAD patients, use of this active agent in clinical practice should be cautiously carried out because of adverse events. [source, 2016]
Clinical studies have established the effectiveness of Quetiapine in treating psychiatric conditions, including obsessive-compulsive disorder, post-traumatic stress disorder, personality disorders, anxiety, and depression. [source, 2015]
The main acute adverse effect of Quetiapine is somnolence, and prescription labels warn to avoid using with alcohol. [source, 2015]